Drugs / GDC-0134
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03807739 | Feb → May 2019 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03237741 | Aug → Dec 2017 | amyotrophic lateral sclerosis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02655614 | May 2016 → Mar 2020 | amyotrophic lateral sclerosis | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-0134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03237741 ↗ |
| Known as | Rg-6000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3732012 ↗ |
| Modality | Small molecule | — CHEMBL3732012 ↗ |
| Route | Oral | “GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.” NCT02655614 ↗ |